Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
November 21 2022 - 9:11AM
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:
CNTX), a women’s oncology company developing novel treatments for
breast and gynecologic cancers, today announced clinical data on
onapristone extended release (ONA-XR) will be presented at the 2022
San Antonio Breast Cancer Symposium® (SABCS®) taking place in San
Antonio, Texas, from December 6-10, 2022.
“We are pleased that ONA-XR will be featured at SABCS. Initial
clinical data from the SMILE trial will be presented, which is
being conducted in collaboration with the Wisconsin Oncology
Network, as well as a presentation providing an early look at the
ELONA trial design that we recently initiated as part of our
collaboration agreement with The Menarini Group. We’re excited to
reconnect with the oncology community at SABCS, to further
highlight the potential of ONA-XR to help improve the lives of
people living with breast cancer, and to work toward creating new
standards of care in the women’s oncology field that will make a
meaningful impact,” said Martin Lehr, CEO of Context
Therapeutics.
Details on the presentations are as follows:
Poster Title: The SMILE Study: A phase II trial of onapristone
in combination with fulvestrant for patients with ER-positive and
HER2-negative metastatic breast cancer after progression on
endocrine therapy and CDK 4/6 inhibitorsPoster ID:
OT2-01-02Abstract: 1300819 Session: Ongoing Trials Poster Session
2Date: Wednesday December 7, 2022Time: 5:00 PM - 6:15 PM
CTPresenters: Sailaja Kamaraju, M.D., Medical College of Wisconsin,
Milwaukee, Wis., and Kari Wisinski, M.D., University of Wisconsin -
Madison
Poster Title: ELONA: An open-label, phase 1b-2 study of
elacestrant, in combination with onapristone in patients with
estrogen receptor-positive, progesterone receptor-positive,
HER2-negative advanced or metastatic breast cancerPoster ID:
OT2-01-04Abstract: 1307318Session: Ongoing Trials Poster Session
2Date: Wednesday December 7, 2022Time: 5:00 PM - 6:15 PM
CTPresenter: Erika Hamilton, M.D., Sarah Cannon Research
Institute
Details on the presentations listed above are also available on
the 2022 SABCS website:
https://www.sabcs.org/2022-Symposium-Overview
About ONA-XRONA-XR (onapristone extended
release) is a potent and specific antagonist of the progesterone
receptor (PR) that is orally administered. Currently, there are no
approved therapies that selectively target PR+ cancers. Preliminary
preclinical and clinical data suggest that ONA-XR has anticancer
activity by inhibiting progesterone receptor binding to chromatin,
downregulating cancer stem cell mobilization and blocking immune
evasion. ONA-XR is currently being evaluated in three Phase 2
clinical trials and one Phase 1b/2 clinical trial in PR+ breast,
ovarian and endometrial cancers. ONA-XR is an investigational drug
that has not been approved for marketing by any regulatory
authority.
About Context Therapeutics®Context Therapeutics
Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical
company committed to advancing medicines for female cancers. The
Company’s pipeline includes small molecule and bispecific antibody
drug candidates that target cancer signaling pathways. Onapristone
extended release (ONA-XR), a novel, first-in-class potent and
selective progesterone receptor antagonist, is currently in three
Phase 2 clinical trials and one Phase 1/2 clinical trial in
hormone-driven breast, ovarian, and endometrial cancers. Context is
also developing a selective Claudin 6 (CLDN6) x CD3 bispecific
antibody for CLDN6 positive tumors, currently in preclinical
development. Context is headquartered in Philadelphia. For
more information, please
visit www.contexttherapeutics.com or follow the Company
on Twitter and LinkedIn.
Forward-looking StatementsThis press release
contains “forward-looking statements” that involve substantial
risks and uncertainties for purposes of the safe harbor provided by
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, included in
this press release regarding strategy, future operations,
prospects, plans and objectives of management, including words such
as "may," "will," "expect," "anticipate," "plan," "intend," and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
forward-looking statements. These include, without limitation,
statements regarding (i) the expectation that initial clinical data
for the SMILE trial and information regarding the ELONA trial
design will be presented at SABCS in December 2022, (ii) the
results of our clinical trials, (iii) the potential benefits of our
product candidates, (iv) the likelihood data will support future
development, and (v) the likelihood of obtaining regulatory
approval of our product candidates. Forward-looking statements in
this release involve substantial risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by the forward-looking statements, and we, therefore cannot
assure you that our plans, intentions, expectations or strategies
will be attained or achieved. Other factors that may cause actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
our filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as otherwise required by law, we disclaim any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Media Contact:Gina Cestari6
Degrees917-797-7904gcestari@6degreespr.com
Investor Relations Contact:Laine YonkerEdison
Grouplyonker@edisongroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Apr 2023 to Apr 2024